

STATEMENT OF PURPOSE

RS24912

The Idaho Board of Pharmacy administers the regulatory provisions of the state's Uniform Controlled Substances Act. If any substance is designated, rescheduled, or deleted as a controlled substance under federal law and notice thereof is given to the Board, the Board shall similarly control the substance under this Act unless the Board objects to the inclusion, rescheduling, or deletion. In 2016, the Drug Enforcement Administration (DEA) scheduled two products: eluxadoline and brivaracetam. This bill mirrors the recent DEA changes, provides additional housekeeping in conformance with federal DEA schedules, and further schedules additional synthetic products that have been reported by the state forensic lab. The bill also clarifies the methods by which the Board of Pharmacy may designate a controlled substance and the timeframe within which such designation may occur.

FISCAL NOTE

This legislation will have no fiscal impact to the general fund or the Board of Pharmacy's dedicated fund. It has no fiscal impact because adding, removing, or re-scheduling products to the Controlled Substances Act does not create any new state program and does not compel any state action.

Contact:

Alex Adams
Board of Pharmacy
(208) 334-2356

DISCLAIMER: This statement of purpose and fiscal note are a mere attachment to this bill and prepared by a proponent of the bill. It is neither intended as an expression of legislative intent nor intended for any use outside of the legislative process, including judicial review (Joint Rule 18).